A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19
|Effective start/end date||8/27/20 → 11/30/20|
- University of California at Los Angeles (AGREEMENT 1560 B WA693 //)
- National Institute of Allergy and Infectious Diseases (AGREEMENT 1560 B WA693 //)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.